[CAS NO. 1422527-84-1] Tafasitamab

Name: Tafasitamab
Brand: Arctom Scientific
SKU: HY-P9981

Ships within

Stock

Price

Qty

Total

$0.00

Please click "REQUEST A QUOTE" button if you need other sizes or custom synthesis

request a quote

If there is no stock, or you need other sizes or custom synthesis, please:

PRODUCTS SPECIFICATIONS [1422527-84-1]

Distributor

Catalog

HY-P9981

Brand

MCE

CAS

1422527-84-1

DESCRIPTION [1422527-84-1]

Overview

MDL	-
Molecular Weight	-
Molecular Formula	-
SMILES	[Tafasitamab]

For research use only. We do not sell to patients.

Summary

Tafasitamab (XmAb5574) is an Fc-modified, humanized monoclonal antibody that binds to the human B-cell surface antigen CD19 ^[1] ^[2] .

In Vitro

Tafasitamab (XmAb5574) induces cytotoxicity against Mino and Jeko (MCL) cell lines in an E/T ratio-dependent manner. Tafasitamab (XmAb5574) increases ADCP and antiproliferative activity. Tafasitamab (XmAb5574) enhances antiproliferative apoptotic activity due to caspase-induced apoptosis ^[1] ^[2] .

MCE has not independently confirmed the accuracy of these methods. They are for reference only.

Cell Cytotoxicity Assay ^[1]

Cell Line:	NHL cell lines and primary CLL and MCL cells by γδ T cells
Concentration:
Incubation Time:	2 h
Result:	Induced killing of NHL cell lines and primary CLL and MCL cells by γδ T cells.

Cell Proliferation Assay ^[2]

Cell Line:	SU-DHL-6 cells
Concentration:
Incubation Time:	72 h
Result:	Showed potent antiproliferative effects on tumor cell.

Apoptosis Analysis ^[2]

Cell Line:	SU-DHL-6 cells
Concentration:	0-4 ng/mL
Incubation Time:	48 h
Result:	Showed potent antiproliferative effects due to caspase-induced apoptosis

In Vivo

Tafasitamab (SC, once on Day 1, 2.5 μg/kg) inhibits lymphoma growth in disseminated BL mouse xenograft tumor models ^[1] .

MCE has not independently confirmed the accuracy of these methods. They are for reference only.

Animal Model:	Disseminated Raji model ^[1] .
Dosage:	2.5 μg/kg
Administration:	Tafasitamab (SC, once on Day 1, 2.5 μg/kg)
Result:	Showed antitumor activity in disseminated Raji model.

Animal Model:	Disseminated Ramos model ^[1] .
Dosage:	10 mg/kg
Administration:	Tafasitamab (IV, on Days 3, 6, 10, 13, 17, and 20 at a dose of 10 mg/kg)
Result:	Showed antitumor activity in disseminated Ramos model.

Clinical Trial

NCT Number	Sponsor	Condition	Start Date	Phase
NCT05583071	University of Cologne\|Incyte Corporation	Non-Hodgkin Lymphoma	January 2023	Phase 2
NCT04978584	M.D. Anderson Cancer Center	Diffuse Large B-Cell Lymphoma	March 3, 2022	Phase 2
NCT05552937	Beijing InnoCare Pharma Tech Co., Ltd.	DLBCL	September 6, 2021	Phase 2
NCT04661007	Incyte Biosciences Japan GK\|Incyte Corporation	Non Hodgkins Lymphoma\|Diffuse Large B-cell Lymphoma	December 15, 2020	Phase 1
NCT02763319	MorphoSys AG\|ICON Clinical Research	Diffuse Large B-cell Lymphoma	June 2016	Phase 2\|Phase 3
NCT02005289	Ohio State University Comprehensive Cancer Center\|MorphoSys AG	Contiguous Stage II Small Lymphocytic Lymphoma\|Noncontiguous Stage II Small Lymphocytic Lymphoma\|Prolymphocytic Leukemia\|Recurrent Small Lymphocytic Lymphoma\|Refractory Chronic Lymphocytic Leukemia\|Stage I Chronic Lymphocytic Leukemia\|Stage I Small Lymphocytic Lymphoma\|Stage II Chronic Lymphocytic Leukemia\|Stage III Chronic Lymphocytic Leukemia\|Stage III Small Lymphocytic Lymphoma\|Stage IV Chronic Lymphocytic Leukemia\|Stage IV Small Lymphocytic Lymphoma	January 17, 2014	Phase 2
NCT04824092	MorphoSys AG	Diffuse Large B-cell Lymphoma	May 11, 2021	Phase 3
NCT01161511	Xencor, Inc.	Chronic Lymphocytic Leukemia\|Small Lymphocytic Lymphoma	September 2010	Phase 1
NCT05328102	Xencor, Inc.	Diffuse Large-cell B-cell Lymphoma	June 30, 2022	Phase 2
NCT04646395	International Extranodal Lymphoma Study Group (IELSG)	Marginal Zone Lymphoma	October 20, 2021	Phase 2
NCT04809467	Incyte Corporation	Chronic Lymphocytic Leukemia\|Non Hodgkin Lymphoma	September 16, 2021	Phase 1\|Phase 2
NCT05429268	Incyte Corporation	Large B-Cell Lymphoma\|Diffuse Large B-Cell Lymphoma	November 16, 2022	Phase 3
NCT05351593	James Rubenstein\|Incyte Corporation\|University of California, San Francisco	CNS Lymphoma\|Primary Central Nervous System Lymphoma\|Secondary Central Nervous System Lymphoma	June 8, 2022	Phase 1\|Phase 2
NCT05205252	Epizyme, Inc.	Relapsed+Refractory	December 22, 2021	Phase 1\|Phase 2
NCT05222555	MorphoSys AG	Diffuse Large B Cell Lymphoma	July 19, 2022	Phase 1\|Phase 2
NCT05615636	M.D. Anderson Cancer Center	Hodgkin Lymphoma\|B-Cell Lymphoma\|Relapsed B-cell NHL	April 30, 2023	Phase 2
NCT04680052	Incyte Corporation	Follicular Lymphoma\|Marginal Zone Lymphoma	April 15, 2021	Phase 3
NCT05453500	University of Washington\|Incyte Corporation	B Acute Lymphoblastic Leukemia, Philadelphia Chromosome Negative	January 1, 2023	Phase 2
NCT04882163	Celgene	Lymphoma, B-Cell	October 10, 2021	Phase 1\|Phase 2
NCT05366218	University Hospital Tuebingen	ALL, Childhood B-Cell\|Acute Lymphoid Leukemia Relapse\|Acute Lymphocytic Leukemia Refractory	December 2022	Phase 1\|Phase 2
NCT04974216	The Lymphoma Academic Research Organisation	DLBCL	December 20, 2021	Phase 2
NCT04607772	Karyopharm Therapeutics Inc	Relapsed or Refractory Diffuse Large B-Cell Lymphoma	November 18, 2020	Phase 1\|Phase 2
NCT02639910	MorphoSys AG	Leukemia, Lymphocytic, Chronic, B-Cell\|Chronic Lymphocytic Leukemia\|Small Lymphocytic Lymphoma	November 2016	Phase 2
NCT05455697	University of Washington	Diffuse Large B-Cell Lymphoma\|Grade 3b Follicular Lymphoma\|High Grade B-Cell Lymphoma	December 15, 2022	Phase 1\|Phase 2
NCT04134936	MorphoSys AG	Diffuse Large B-cell Lymphoma	December 11, 2019	Phase 1
NCT03930953	Celgene	Lymphoma, Non-Hodgkin	May 20, 2019	Phase 1
NCT05626322	Pfizer\|MorphoSys AG\|Incyte Corporation	Diffuse Large B-Cell Lymphoma	December 7, 2022	Phase 2

Appearance

Liquid

Shipping

Shipping with dry ice.

Storage

Please store the product under the recommended conditions in the Certificate of Analysis.